Home > Neurology > AAN 2022 > Multiple Sclerosis > Ublituximab versus teriflunomide in relapsing MS patients

Ublituximab versus teriflunomide in relapsing MS patients

Presented By
Prof. Lawrence Steinman, Stanford University, CA, USA
Conference
AAN 2022
Trial
Phase 3, ULTIMATE I; ULTIMATE II
Doi
https://doi.org/10.55788/b70402f6
In both the phase 3 ULTIMATE I and ULTIMATE II trial, ublituximab treatment demonstrated a statistically significant reduction in annualised relapse rate (ARR) and cumulative probability of first relapse compared with teriflunomide over 96 weeks in patients with relapsing multiple sclerosis (RMS). Ublituximab is an investigational monoclonal antibody that targets a unique epitope on the CD20 antigen [1]. Binding to B cells, ublituximab triggers a series of immunological reactions, including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). It is glyco-engineered to enhance ADCC [2]. ULTIMATE I (NCT03277261) (n=549) and ULTIMATE II (NCT03277248) (n=545) are 2 independent phase 3, randomised, double-blind, active-con...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on